

## Table of Contents

---

Abstract	i
Declaration	v
Certificate of the Principal Supervisor	vi
Certificate of the External Examiner and ODEC	vii
Acknowledgements	viii
Table of Contents	x
List of Figures	xviii
List of Tables	xxii
List of Abbreviations	xxxi
List of Publications	
Conference Proceedings	

CHAPTER NO.	Name of the Chapter	Page No.
CHAPTER 1 :	Motivation and Outline of the Thesis	
1.1	Motivation of the present work	1
1.2	Outline of the thesis	3
CHAPTER 2 : Introduction and Review of Literature		
2.1	Protein folding and misfolding	5
2.2	Protein aggregation	6
2.3	Intrinsically disordered protein and its link to protein aggregation	9
2.4	Neurodegenerative disease	10
2.5	Alzheimer's disease (AD)	11
2.5.1	Background of AD	12
2.5.2	Occurrence and symptoms of AD	13
2.5.3	Occurrence of AD in India	15
2.5.4	Causes of AD	15
2.5.5	Amyloid-Beta (A $\beta$ ) peptide	16
2.5.5.1	Production of A $\beta$ peptide from APP	17

## **Contents**

---

2.5.5.2 Functions of A $\beta$ <sub>1-42</sub> peptide	18
2.5.5.3 Monomers of A $\beta$ <sub>1-42</sub> peptide	19
2.5.5.4 Dimerization of A $\beta$ <sub>1-42</sub> peptide	19
2.5.5.5 Oligomers and fibrils of A $\beta$ <sub>1-42</sub> Peptide	20
2.5.6 Effects of Mutations Linked with Inherited AD	21
2.5.7 Inhibitors of A $\beta$ <sub>1-42</sub> peptide aggregation and current treatment of AD	22
2.6 Parkinson's disease (PD)	23
2.6.1 Background of PD	23
2.6.2 Occurrence and symptoms of PD	24
2.6.3 Occurrence of PD in India	25
2.6.4 Causes of PD	26
2.6.5 Alpha-Synuclein ( $\alpha$ S) protein	27
2.6.5.1 Functions of $\alpha$ -Synuclein	30
2.6.5.2 Association of $\alpha$ -Synuclein protein with PD	31
2.6.5.3 Mutations in $\alpha$ -Synuclein	32
2.6.5.4 Aggregation of $\alpha$ -Synuclein	33
2.6.5.5 Important factors for the aggregation mechanism of $\alpha$ -Synuclein	34
2.6.5.6 Proto-fibrils of $\alpha$ -Synuclein	35
2.6.5.7 Membrane interactions of $\alpha$ -Synuclein	36
2.6.6 Inhibitors of $\alpha$ -Synuclein aggregation and current treatment of PD	37
2.7 Interaction of A $\beta$ <sub>1-42</sub> peptide and $\alpha$ -Synuclein	38
2.7.1 Synergistic interactions between Amyloid- $\beta$ and $\alpha$ -Synuclein	39
2.7.2 Direct interactions between Amyloid- $\beta$ and $\alpha$ -Synuclein	40
2.8 Scope of the Thesis	41
2.9 Main Objectives of the Thesis	42

## **CHAPTER 3 : Materials and Methods**

3.1 Tools and Techniques	43
3.1.1 Molecular dynamics (MD) simulation	43
3.1.1.1 History of MD Simulation	43
3.1.1.2 Theory of MD Simulation	44

---

---

**Contents**

---

3.1.1.3	Force field (FF)	46
3.1.1.4	Long range interactions: Ewald sum	48
3.1.1.5	Dealing with molecules: SHAKE algorithm	49
3.1.1.6	Periodic Boundary conditions	50
3.1.1.7	Temperature and Pressure computation and control	51
3.1.1.8	Water molecule models	53
3.1.1.9	Molecular Dynamics steps	54
3.1.2	Potential of mean force (PMF)	58
3.1.2.1	Umbrella Sampling (US)	58
3.1.2.2	Running the umbrella sampling calculations	59
3.1.2.3	The weighted histogram analysis method (WHAM) for free-energy calculations	60
3.1.3	The molecular mechanics energies combined with the Poisson Boltzmann or generalized Born and surface area continuum solvation method (MM-PBSA and MM-GBSA)	61
3.1.4	PDBsum	64
3.1.5	Molecular Docking	66
3.1.6	In-silico prediction of protein-protein interaction	68
3.1.7	3-D structure visualization tools	69
3.1.8	Analysis of MD Trajectories	70

---

**CHAPTER 4 : Study of the effect of ionic strength on A<sub>β</sub><sub>1-42</sub> aggregation**

4.1	Abstract	73
4.2	Introduction	74
4.3	Materials & Methods	76
4.3.1	Preparation of the Initial Structures	76
4.3.2	Molecular Dynamics Simulation protocol	77
4.3.3	Analysis of the MD Trajectories	79

## Contents

---

4.4 Results and discussion	79
4.4.1 Interpretations of MD Trajectories for A $\beta$ <sub>1-42</sub> Peptide in the three Explicit Systems	79
4.4.2 Analysis of Secondary Structure	81
4.4.3 Analysis of Conformational Snapshots	82
4.4.4 Analysis of Hydrogen bonds	84
4.4.5 Analysis of Diffusion Coefficient	90
4.5 Conclusion	91

## CHAPTER 5 : Study of the effect of peptides on dimerization and aggregation of A $\beta$ <sub>1-42</sub> peptide

5.1 Abstract	93
5.2 Introduction	93
5.3 Materials & Methods	96
5.3.1 Molecular docking and the preparation of the initial structure	96
5.3.1.1 Preparation of receptor	96
5.3.1.2 Preparation of ligand	96
5.3.1.3 Preparation of A $\beta$ <sub>1-42</sub> -A $\beta$ <sub>1-42</sub> homodimer complex	96
5.3.1.4 Preparation of A $\beta$ <sub>1-42</sub> -CTerm heterodimer complex	98
5.3.2 Molecular Dynamics (MD) simulation of A $\beta$ <sub>1-42</sub> -A $\beta$ <sub>1-42</sub> Homodimer and A $\beta$ <sub>1-42</sub> -CTerm Heterodimer complexes	100
5.3.3 Potential of Mean Force (PMF) calculation	101
5.3.4 MMPBSA/ GBSA Binding free energy calculation	102
5.4 Results and discussion	102
5.4.1 Potential of Mean Force (PMF) profile	102
5.4.2 Binding Free Energy (BFE) Analysis	105
5.4.3 Contribution of individual residues in the formation of A $\beta$ <sub>1-42</sub> -A $\beta$ <sub>1-42</sub> Homodimer complex and A $\beta$ <sub>1-42</sub> -CTerm Heterodimer complex	108
5.5 Conclusion	110

---

**CHAPTER 6: Study of the role of small molecule inhibitor in preventing aggregation of A $\beta$ <sub>1-42</sub> peptide**

6.1 Abstract	111
6.2 Introduction	111
6.3 Materials & Methods	113
6.3.1 System preparation	113
6.3.1.1 Preparation of receptor	113
6.3.1.2 Preparation of ligand	113
6.3.1.3 Preparation of the complex	114
6.3.2 Setup for MD simulations	116
6.3.3 Analysis of the MD Trajectories	116
6.3.4 MMPBSA/ GBSA Binding free energy and PRED calculation	117
6.4 Results and Discussion	117
6.4.1 Molecular docking of RSV with A $\beta$ <sub>1-42</sub> peptide monomer	117
6.4.2 RSV maintains A $\beta$ <sub>1-42</sub> peptide monomer stability and avoids conformational change	118
6.4.2.1 Effect of RSV on the structural stability of A $\beta$ <sub>1-42</sub> peptide monomer	119
6.4.2.1.1 Root Mean Square Deviation (RMSD) analysis	119
6.4.2.1.2 Root Mean Square Fluctuation (RMSF) Analysis	120
6.4.2.1.3 Radius of gyration (R <sub>g</sub> ) Analysis	121
6.4.2.1.4 Solvent Accessible Surface Area (SASA) Analysis	121
6.4.2.2 Secondary structure analysis of A $\beta$ <sub>1-42</sub> peptide monomer and (A $\beta$ <sub>1-42</sub> peptide + RSV) complex	122
6.4.3 Analysis of the conformational dynamics	124
6.4.4 Hydrogen bond analysis	125
6.4.5 RSV destabilizes the salt-bridge distance (D23-K28) in (A $\beta$ <sub>1-42</sub> peptide + RSV) complex	139
6.4.6 Binding free energy analysis between RSV and A $\beta$ <sub>1-42</sub> peptide monomer	142
6.4.7 Per-residue energy decomposition (PRED) analysis	143

---

## **Contents**

---

6.5 Conclusion	144
----------------	-----

### **CHAPTER 7: Study of inhibition of $\alpha$ -Synuclein aggregation using crowding agents**

7.1 Abstract	146
7.2 Introduction	146
7.3 Materials & Methods	148
7.3.1 System Preparation	148
7.3.1.1 Preparation of receptor	148
7.3.1.2 Preparation of crowding agent	148
7.3.1.3 Preparation of the complexes	148
7.3.2 Setup for MD simulations	149
7.4 Results and Discussion	149
7.4.1 Analysis of the conformational changes observed during different intervals of simulation period	149
7.4.2 Structural properties of the complexes from the MD simulation	152
7.4.2.1 Root Mean Square Deviation (RMSD) analysis	152
7.4.2.2 Root Mean Square Fluctuation (RMSF) Analysis	154
7.4.2.3 Radius of gyration ( $R_g$ ) Analysis	155
7.4.3 Secondary structure analysis	155
7.4.4 Analysis of Diffusion Coefficient	158
7.5 Conclusion	159

### **CHAPTER 8 : Study of the effect of peptides on $\alpha$ -Synuclein aggregation**

8.1 Abstract	160
8.2 Introduction	161
8.3 Materials & Methods	162
8.3.1 Preparation of the system	162

---

---

**Contents**

---

8.3.1.1 Preparation of the ligands	162
8.3.1.2 Preparation of the receptor	162
8.3.1.3 Preparation of the complexes	162
8.3.2 Molecular Dynamics (MD) simulation of ( $\alpha$ -Synuclein-K84s) and ( $\alpha$ -Synuclein-K102s) complexes	163
8.3.3 MD analyses	163
8.3.4 Binding free energy	164
8.4 Results and Discussion	164
8.4.1 Structural properties of the ( $\alpha$ -Synuclein-K84s) and ( $\alpha$ -Synuclein-K102s) complexes from the MD simulation	164
8.4.1.1 Root Mean Square Deviation (RMSD) analysis	164
8.4.1.2 Root Mean Square Fluctuation (RMSF) Analysis	166
8.4.2 Hydrogen bond analysis	168
8.4.3 Contribution of interface residues	170
8.4.4 Secondary structure analysis calculation	177
8.4.5 Binding free energy calculation	179
8.5 Conclusion	183

CHAPTER 9 : Study of the role of natural compound in preventing aggregation of  $\alpha$ -Synuclein

9.1 Abstract	184
9.2 Introduction	184
9.3 Materials & Methods	185
9.3.1 Molecular docking and the preparation of initial structures	185
9.3.1.1 Preparation of receptor	185
9.3.1.2 Preparation of ligand	185
9.3.1.3 Preparation of the complex	186
9.3.2. Setup for MD simulations	188
9.3.3 MMPBSA/ GBSA Binding free energy calculation	189
9.4 Results and Discussion	189

## **Contents**

---

9.4.1	Conformational analysis of $\alpha$ -Synuclein (apo) and ( $\alpha$ -Synuclein + OleA) complex	189
9.4.1.1	Root Mean Square Deviation (RMSD) analysis	189
9.4.1.2	Radius of gyration ( $R_g$ ) Analysis	190
9.4.1.3	Solvent Accessible Surface Area (SASA) Analysis	190
9.4.1.4	B-factor analysis	191
9.4.2	Analysis of the conformational changes observed during different intervals of simulation period	194
9.4.3	Secondary structure analysis	199
9.4.4	Hydrogen bond analysis	201
9.4.5	Analysis of the hydrophobic contacts	205
9.4.6	Analysis of the distance between NAC and C-terminal domains for the two systems	206
9.4.7	MM-PBSA and MM-GBSA calculations of ( $\alpha$ -Synuclein + OleA) complex	208
9.5	Conclusion	216
CHAPTER 10 Summary and Future Prospects		
10.1	Overview of Results	217
10.2	Future Prospects	220
BIBLIOGRAPHY		221